US pharma major Eli Lilly (NYSE: LLY) has entered into a multi-million dollar agreement for the discovery and development of translation inhibitors for several target proteins by using Anima Biotech's translation control therapeutics platform.
The multi-year agreement is structured as an exclusive collaboration around several undisclosed Lilly targets. Anima, which has previously raised $30 million, including $10 million in National Institutes for Health (NIH) research grants, will use its technology platform to discover lead candidates that are translation inhibitors of the Lilly targets. Lilly will be responsible for clinical development and commercialization of products resulting from the collaboration.
Financial terms of the collaboration
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze